Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Evofem Biosciences's shares outstanding was 137M at Jun 30, 2026. For fiscal 2025 it was 6.42B, up 7926.9% from the year before. Over ten years it grew 370.1% a year on average. The highest annual figure on record is 6.42B in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.42B | +7926.9% |
| FY2024 | Dec 31, 2024 | 80M | -91.9% |
| FY2023 | Dec 31, 2023 | 984M | +211082.0% |
| FY2022 | Dec 31, 2022 | 0M | +567.4% |
| FY2021 | Dec 31, 2021 | 0M | +94.9% |
| FY2020 | Dec 31, 2020 | 0M | +66.9% |
| FY2019 | Dec 31, 2019 | 0M | +83.7% |
| FY2018 | Dec 31, 2018 | 0M | +1017.7% |
| FY2017 | Dec 31, 2017 | 0M | -14.8% |
| FY2016 | Dec 31, 2016 | 0M | +0.8% |
| FY2015 | Dec 31, 2015 | 0M | +579.9% |
| FY2014 | Dec 31, 2014 | 0M | +289.1% |
| FY2013 | Dec 31, 2013 | 0M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 137M | +14.0% |
| Q1 FY2026 | Mar 31, 2026 | 133M | -97.8% |
| Q4 FY2025 | Dec 31, 2025 | 146M | +16.5% |
| Q3 FY2025 | Sep 30, 2025 | 120M | +24.0% |
| Q2 FY2025 | Jun 30, 2025 | 120M | -92.5% |
| Q1 FY2025 | Mar 31, 2025 | 6.16B | +19631.2% |
| Q4 FY2024 | Dec 31, 2024 | 125M | +7845.9% |
| Q3 FY2024 | Sep 30, 2024 | 96M | +7486.1% |
| Q2 FY2024 | Jun 30, 2024 | 1.61B | +179859.7% |
| Q1 FY2024 | Mar 31, 2024 | 31M | +602.3% |
| Q2 FY2023 | Jun 30, 2023 | 2M | +626.2% |
| Q1 FY2023 | Mar 31, 2023 | 1M | +1332.8% |
| Q4 FY2022 | Dec 31, 2022 | 1M | +940.7% |
| Q3 FY2022 | Sep 30, 2022 | 4M | +5298.9% |
| Q2 FY2022 | Jun 30, 2022 | 0M | +225.1% |
| Q1 FY2022 | Mar 31, 2022 | 0M | +103.3% |
| Q4 FY2021 | Dec 31, 2021 | 0M | +98.7% |
| Q3 FY2021 | Sep 30, 2021 | 0M | +90.0% |
| Q2 FY2021 | Jun 30, 2021 | 0M | +116.9% |
| Q1 FY2021 | Mar 31, 2021 | 0M | +69.8% |
| Q4 FY2020 | Dec 31, 2020 | 0M | +60.6% |
| Q3 FY2020 | Sep 30, 2020 | 0M | +75.6% |
| Q2 FY2020 | Jun 30, 2020 | 0M | +57.1% |
| Q1 FY2020 | Mar 31, 2020 | 0M | +79.3% |
| Q4 FY2019 | Dec 31, 2019 | 0M | +95.8% |
| Q3 FY2019 | Sep 30, 2019 | 0M | +79.4% |
| Q2 FY2019 | Jun 30, 2019 | 0M | +76.0% |
| Q1 FY2019 | Mar 31, 2019 | 0M | +79.5% |
| Q4 FY2018 | Dec 31, 2018 | 0M | +1219.8% |
| Q3 FY2018 | Sep 30, 2018 | 0M | +1215.6% |
| Q2 FY2018 | Jun 30, 2018 | 0M | +965.1% |
| Q1 FY2018 | Mar 31, 2018 | 0M | +664.2% |
| Q4 FY2017 | Dec 31, 2017 | 0M | -15.2% |
| Q3 FY2017 | Sep 30, 2017 | 0M | -14.9% |
| Q2 FY2017 | Jun 30, 2017 | 0M | -14.8% |
| Q1 FY2017 | Mar 31, 2017 | 0M | – |
| Q4 FY2016 | Dec 31, 2016 | 0M | – |
| Q3 FY2016 | Sep 30, 2016 | 0M | – |
| Q2 FY2016 | Jun 30, 2016 | 0M | – |
See a number that looks wrong?